PL2542576T3 - Sposoby badań przesiewowych przeciwciał - Google Patents

Sposoby badań przesiewowych przeciwciał

Info

Publication number
PL2542576T3
PL2542576T3 PL11751155.0T PL11751155T PL2542576T3 PL 2542576 T3 PL2542576 T3 PL 2542576T3 PL 11751155 T PL11751155 T PL 11751155T PL 2542576 T3 PL2542576 T3 PL 2542576T3
Authority
PL
Poland
Prior art keywords
methods
screening antibodies
antibodies
screening
Prior art date
Application number
PL11751155.0T
Other languages
English (en)
Inventor
Robert Lyon
Dennis Benjamin
Maureen Ryan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2542576T3 publication Critical patent/PL2542576T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531Production of immunochemical test materials
    • G01N33/532Production of labelled immunochemicals
    • G01N33/533Production of labelled immunochemicals with fluorescent label
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL11751155.0T 2010-03-02 2011-02-28 Sposoby badań przesiewowych przeciwciał PL2542576T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30972510P 2010-03-02 2010-03-02
US32343310P 2010-04-13 2010-04-13

Publications (1)

Publication Number Publication Date
PL2542576T3 true PL2542576T3 (pl) 2016-10-31

Family

ID=44542524

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11751155.0T PL2542576T3 (pl) 2010-03-02 2011-02-28 Sposoby badań przesiewowych przeciwciał

Country Status (10)

Country Link
US (2) US9725500B2 (pl)
EP (1) EP2542576B1 (pl)
JP (5) JP5797210B2 (pl)
CN (1) CN102858798B (pl)
CA (1) CA2788289C (pl)
DK (1) DK2542576T3 (pl)
ES (1) ES2581314T3 (pl)
PL (1) PL2542576T3 (pl)
PT (1) PT2542576T (pl)
WO (1) WO2011109308A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10107782B2 (en) 2008-01-25 2018-10-23 ProteinSimple Method to perform limited two dimensional separation of proteins and other biologicals
PL2542576T3 (pl) * 2010-03-02 2016-10-31 Sposoby badań przesiewowych przeciwciał
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
WO2013155634A1 (en) 2012-04-19 2013-10-24 Jiaqi Wu Dual wavelength isoelectric focusing for determining drug load in antibody drug conjugates
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
EP3564259A3 (en) 2012-11-09 2020-02-12 Innate Pharma Recognition tags for tgase-mediated conjugation
US10611824B2 (en) * 2013-03-15 2020-04-07 Innate Pharma Solid phase TGase-mediated conjugation of antibodies
GB2513405A (en) 2013-04-26 2014-10-29 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resins
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
US9766206B2 (en) 2013-09-27 2017-09-19 ProteinSimple Apparatus, systems, and methods for capillary electrophoresis
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
SG11201700365TA (en) 2014-07-24 2017-02-27 Genentech Inc Methods of conjugating an agent to a thiol moiety in a protein that contains at least one trisulfide bond
GB201419185D0 (en) * 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
CN116059395A (zh) * 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
CN109843919A (zh) 2016-03-25 2019-06-04 西雅图基因公司 用于制备聚乙二醇化的药物-接头及其中间体的方法
KR102648564B1 (ko) 2017-03-24 2024-03-19 씨젠 인크. 글루쿠로니드 약물-링커의 제조 공정 및 그 중간물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
AU2002305478A1 (en) 2001-06-20 2003-01-08 Molecular Staging, Inc. Conjugates of reduced antibodies and biomolecules
AU2002321204B2 (en) * 2001-07-16 2008-05-08 Janssen Pharmaceutica N.V. Improved process for preparing benzimidazole-type compounds
US20090068178A1 (en) * 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
US20030232386A1 (en) * 2002-06-17 2003-12-18 Shah Dinesh O. Assay conjugate and uses thereof
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US20040038331A1 (en) 2002-08-23 2004-02-26 Reddy M. Parameswara Solid phase synthesis of biomolecule conjugates
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
JP4942643B2 (ja) 2004-03-02 2012-05-30 シアトル ジェネティックス, インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
CN109045307A (zh) * 2004-06-01 2018-12-21 健泰科生物技术公司 抗体-药物偶联物和方法
NZ579482A (en) 2004-06-01 2011-02-25 Genentech Inc Antibody drug conjugates and methods
DK1912677T3 (da) 2005-06-20 2014-01-13 Psma Dev Company L L C PSMA-antistof-lægemiddel-konjugater
EP1942944A2 (en) 2005-10-31 2008-07-16 Genentech, Inc. Macrocyclic depsipeptide antibody-drug conjugates and methods
WO2007149932A2 (en) * 2006-06-22 2007-12-27 Genentech, Inc. Methods and compositions for targeting hepsin
BRPI0717638A2 (pt) * 2006-10-27 2013-11-12 Genentech Inc Anticorpors e imunoconjugados e usos para os mesmos
US20080233660A1 (en) 2007-03-23 2008-09-25 Mu Bioteknik Ab Solid phase labeling method
DK2211904T3 (en) * 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
WO2011005818A1 (en) 2009-07-08 2011-01-13 Bio-Rad Laboratories, Inc. Purification of monoclonal antibodies
PL2542576T3 (pl) * 2010-03-02 2016-10-31 Sposoby badań przesiewowych przeciwciał

Also Published As

Publication number Publication date
JP5797210B2 (ja) 2015-10-21
JP6813928B2 (ja) 2021-01-13
CA2788289C (en) 2018-08-21
DK2542576T3 (en) 2016-08-01
US20120322686A1 (en) 2012-12-20
JP2013521498A (ja) 2013-06-10
ES2581314T3 (es) 2016-09-05
WO2011109308A1 (en) 2011-09-09
JP2016216502A (ja) 2016-12-22
CN102858798B (zh) 2015-06-17
HK1180345A1 (zh) 2013-10-18
EP2542576A4 (en) 2013-09-04
US9725500B2 (en) 2017-08-08
EP2542576B1 (en) 2016-04-20
CA2788289A1 (en) 2011-09-09
JP2015227891A (ja) 2015-12-17
JP5998261B2 (ja) 2016-09-28
JP2019167339A (ja) 2019-10-03
EP2542576A1 (en) 2013-01-09
JP6505882B2 (ja) 2019-04-24
JP6291540B2 (ja) 2018-03-14
CN102858798A (zh) 2013-01-02
US20170298118A1 (en) 2017-10-19
PT2542576T (pt) 2016-07-14
JP2018076386A (ja) 2018-05-17

Similar Documents

Publication Publication Date Title
PT2542576T (pt) Métodos para rastreio de anticorpos
ZA201209004B (en) Anti-fgfr2 antibodies
GB201000467D0 (en) Antibodies
IL221371A0 (en) Anti-lrp6 antibodies
IL249501A0 (en) A process for creating antibodies
IL220404A (en) Antiseptic antibodies
ZA201302459B (en) Antibodies
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
SMT201800462T1 (it) Anticorpi umanizzati anti-cd28
GB201020738D0 (en) Antibodies
PT2603528T (pt) Anticorpos glicosilados em fab
EP2558587A4 (en) METHOD FOR DISPLAYING ANTIBODIES
IL222533A0 (en) Methods for detecting antibodies
GB201002238D0 (en) Antibodies
LT2558499T (lt) Antikūnai prieš vla-4
GB201120317D0 (en) Screening method
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
GB201013373D0 (en) Screening apparatus
GB201015419D0 (en) Screening method
GB201015416D0 (en) Screening method
GB201006496D0 (en) Screening method
GB201020751D0 (en) Antibodies
GB201005062D0 (en) Antibodies
GB201105572D0 (en) Screening method-III